You have 9 free searches left this month | to do more

bevacizumab

Bevacizumab is a drug used to treat Colorectal Cancer, Breast Cancer, Ovarian Cancer, and other conditions. Bevacizumab is being actively studied in 302 studies and prior, has been studied in 697.

Top SponsorsTop SitesTop Investigators
National Cancer Institute (NCI)Dana-Farber Cancer InstituteDuNan
Hoffmann-La RocheWashington University School of MedicinePeter C. Enzinger, MD
M.D. Anderson Cancer CenterMassachusetts General HospitalVassilis Georgoulias, MD
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +8 more
  • Bevacizumab
  • Irinotecan Sucrosofate
  • Chicago, Illinois
    Northwestern University
2022-03-10
Mar 10, 2022
M
Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases
Recruiting
  • BRAF V600 Wild Type
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-03-01
Mar 1, 2022
M
Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative
Active, not recruiting
  • Invasive Breast Carcinoma
  • Triple-Negative Breast Carcinoma
  • Bevacizumab
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-02-18
Feb 18, 2022
M
Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer
Recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +5 more
  • Bevacizumab
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-02-24
Feb 24, 2022
N
Testing of Bevacizumab, Erlotinib, and Atezolizumab for Advanced-Stage Kidney Cancer
Recruiting
  • Advanced Papillary Renal Cell Carcinoma
  • +6 more
  • Atezolizumab
  • +2 more
  • Bethesda, Maryland
    National Cancer Institute LAO
2021-10-15
Oct 15, 2021
N
Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases
Active, not recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +2 more
  • Bevacizumab
  • +2 more
  • Los Angeles, California
  • +17 more
2022-01-25
Jan 25, 2022
N
Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Recruiting
  • Metastatic Colorectal Carcinoma
  • +4 more
  • Bevacizumab
  • +4 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
2021-12-14
Dec 14, 2021
N
A Study to Determine Whether Chemotherapy, Bevazicumab, and Atezolizumab is Better Than Chemotherapy Alone in Patients With Advanced Liver Cancer
Recruiting
  • Combined Hepatocellular Carcinoma and Cholangiocarcinoma
  • +4 more
  • Atezolizumab
  • +3 more
  • Danville, Illinois
  • +5 more
2022-03-30
Mar 30, 2022
N
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
Active, not recruiting
  • Adult Glioblastoma
  • +23 more
  • Bevacizumab
  • +3 more
  • Boston, Massachusetts
  • +2 more
2021-11-17
Nov 17, 2021
C
Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC
Recruiting
  • Locally Advanced Lung Non-Small Cell Carcinoma
  • +9 more
  • Duarte, California
  • +3 more
2021-11-15
Nov 15, 2021
A
Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer
Active, not recruiting
Has Results
  • Metastatic Colorectal Carcinoma
  • +5 more
  • Phoenix, Arizona
  • +9 more
2022-01-05
Jan 5, 2022
M
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
Active, not recruiting
  • Appendix Adenocarcinoma
  • +20 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-02-25
Feb 25, 2022
K
Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer
Not yet recruiting
  • Carcinoma, Ovarian Epithelial
  • pembrolizumab
  • +5 more
  • (no location specified)
2021-12-09
Dec 9, 2021
A
Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery - 2019
Completed
Has Results
  • Colorectal Adenocarcinoma
  • +4 more
  • Bevacizumab
  • +4 more
  • Scottsdale, Arizona
  • +12 more
2022-01-27
Jan 27, 2022
M
Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers
Recruiting
  • Cervical Adenocarcinoma
  • +47 more
  • Bevacizumab
  • +3 more
  • Phoenix, Arizona
  • +3 more
2022-01-07
Jan 7, 2022
N
Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Active, not recruiting
  • Fallopian Tube Endometrioid Adenocarcinoma
  • +7 more
  • Anetumab Ravtansine
  • +2 more
  • Orange, California
  • +22 more
2022-04-05
Apr 5, 2022
N
Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma
Active, not recruiting
  • Recurrent Glioblastoma
  • Bevacizumab
  • +3 more
  • La Jolla, California
  • +26 more
2022-03-25
Mar 25, 2022
N
Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma
Recruiting
  • Peritoneal Malignant Mesothelioma
  • Atezolizumab
  • +5 more
  • Chicago, Illinois
  • +8 more
2022-03-15
Mar 15, 2022
T
A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian Cancer
Recruiting
  • Ovarian Cancer
  • Bevacizumab
  • +2 more
  • Tai'an, Shandong, China
    The Second Affiliated Hospital of Shandong First Medical Univers
2021-12-24
Dec 24, 2021
S
Effect of Bevacizumab on Asymptomatic Radiotherapy-induced Brain Injury
Recruiting
  • Brain Injuries
  • Bevacizumab
  • Guangzhou, Guangdong, China
    Sun Yat-Sen Memorial Hospital
2022-03-20
Mar 20, 2022
S
Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer
Recruiting
  • Colorectal Cancer
  • FOLFOX regimen
  • +3 more
  • Madrid, Spain
    Spanish Cooperative Group for the Treatment of Digestive Tumors
2022-03-08
Mar 8, 2022
D
Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma
Active, not recruiting
  • Glioblastoma
  • Boston, Massachusetts
  • +4 more
2022-03-14
Mar 14, 2022
N
Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma
Recruiting
  • Metastatic Alveolar Soft Part Sarcoma
  • Unresectable Alveolar Soft Part Sarcoma
  • Phoenix, Arizona
  • +42 more
2022-02-08
Feb 8, 2022
A
Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab
Recruiting
  • Advanced Colorectal Carcinoma
  • +15 more
  • Bevacizumab
  • +6 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
2021-11-08
Nov 8, 2021
G
Super-Selective Intraarterial Intracranial Infusion of Bevacizumab (Avastin) for Glioblastoma Multiforme
Recruiting
  • Glioblastoma Multiforme
  • Bevacizumab
  • Philadelphia, Pennsylvania
    (unnamed)
2022-03-14
Mar 14, 2022